当前位置: X-MOL 学术Eur. J. Heart Fail. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2024-11-19 , DOI: 10.1002/ejhf.3515
Sharmistha Datta Gupta, Jawad H. Butt, Eoghan G.M. McMurray, Atefeh Talebi, Shingo Matsumoto, Adel R. Rizkala, Alasdair D. Henderson, Akshay S. Desai, Martin Lefkowitz, Milton Packer, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, John J.V. McMurray

Beta-blockers may inhibit neprilysin activity and conversely, neprilysin inhibition may have a sympatho-inhibitory action. Consequently, sacubitril/valsartan may have a greater effect in patients not receiving a beta-blocker compared to those treated with a beta-blocker.

中文翻译:


根据背景 β 受体阻滞剂治疗沙库巴曲/缬沙坦对心力衰竭和射血分数降低患者的影响:来自 PARADIGM-HF 的见解



β 受体阻滞剂可能抑制脑啡肽酶活性,相反,脑啡肽酶抑制可能具有交感神经抑制作用。因此,与接受 β 受体阻滞剂治疗的患者相比,沙库巴曲/缬沙坦对未接受 β 受体阻滞剂的患者可能具有更大的效果。
更新日期:2024-11-20
down
wechat
bug